Influencing factors for hemolytic anemia in patients with chronic hepatitis C treated by ribavirin combined with pegylated interferon-α

Xu JinFeng; Zhang XiaoHui; Liu YaLi; Zhang Jing

doi:10.3969/j.issn.1001-5256.2019.02.015

Volume 35 Issue 2

Feb. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(2): 319-322

PDF( 1840 KB)

Influencing factors for hemolytic anemia in patients with chronic hepatitis C treated by ribavirin combined with pegylated interferon-α

DOI: 10.3969/j.issn.1001-5256.2019.02.015

Department of Hepatitis C & Toxic Liver Diseases, Beijing YouAn Hospital, Capital Medical University

Published Date: 2019-02-20

Abstract

Abstract

Objective To investigate the influencing factors for ribavirin ( RBV) -induced hemolytic anemia during the treatment of chronic hepatitis C using RBV combined with pegylated interferon-α ( PEG-IFNα) , and to provide a reference for early prediction of RBV-related hemolytic anemia in clinical practice. Methods A total of 235 patients with chronic hepatitis C who were given antiviral therapy with PEG-IFNα combined with RBV in Beijing YouAn Hospital from March 2016 to March 2018 were enrolled. Parameters of routine blood test, liver function parameters, liver stiffness measurement, HCV RNA, HCV viral genotype, and inosine triphosphate pyrophosphatase ( ITPA) genotype were determined before the antiviral therapy, and routine blood tests were performed at weeks 2, 4, 8, and 12 of treatment. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for non-normally distributed continuous data between groups; the chi-square test or the Fisher's exact test was used for comparison of categorical data between groups. Univariate analysis and multivariate logistic regression analyses were used to determine the influencing factors for RBV-related hemolytic anemia, and a predictive model was established accordingly; the receiver operating characteristic curve was used to analyze the predictive value of this model for RBV-related hemolytic anemia. Results At weeks 2, 4, 8, and 12 of treatment, the ITPA ( rs1127354) genotype CC group had a significantly greater reduction in hemoglobin ( Hb) than the ITPA ( rs1127354) genotype AA + AC group ( all P < 0. 05) . At week 4 of treatment, there was a significant difference between the AA + AC group and the CC group in the proportion of patients with a > 30 g/L reduction in Hb ( 2. 38% vs 39. 9%, X2= 23. 175, P < 0. 001) or an Hb level of < 100 g/L ( 0 vs10. 88%, P = 0. 018) . The degree of reduction in Hb at week 2 ( odds ratio ( OR) = 1. 073, P < 0. 001) , ITPA ( rs1127354) genotype ( OR = 18. 920, P = 0. 005) , and baseline Hb level ( OR = 1. 032, P = 0. 024) were independent risk factors for a > 30 g/L reduction in Hb at week 4. Conclusion Patients with ITPA ( rs1127354) genotype CC tend to develop RBV-related hemolytic anemia. ITPA ( rs1127354) genotype, baseline Hb level, and degree of reduction in Hb at week 2 can be used to predict the development of RBV-related hemolysis during anti-HCV treatment, in order to achieve early warning and guide early intervention.
- hepatitis C, chronic,
- anemia, hemolytic,
- ribavirin,
- risk factors

FullText(HTML)

References(14)

References

[1]European Association for the Study of the Liver.EASL clinical practice guidelines:Management of chronic hepatitis B virus infection[J].J Hepatol, 2012, 57 (1) :167-185.

[2]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:A 2015 update[J].JClin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[3]LI Y, LIU L, LUO SL, et al.Association of direct-acting antiviral therapy for hepatitis C with the development and recurrence of liver cancer[J].J Clin Hepatol, 2018, 34 (2) :410-413. (in Chinese) 李砚, 刘蕾, 罗书兰, 等.丙型肝炎直接抗病毒治疗与肝癌发生及复发的关系[J].临床肝胆病杂志, 2018, 34 (2) :410-413.

[4]GAETA GB, PRECONE DF, FELACO FM, et al.Premature discontinuation of interferon plus ribavirin for adverse effects:A multicentre survey in'real world'patients with chronic hepatitis C[J].Aliment Pharmacol Ther, 2002, 16 (9) :1633-1639.

[5]FELLAY J, THOMPSON AJ, GE D, et al.ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C[J].Nature, 2010, 464 (7287) :405-408.

[6]LIU Z, WANG S, QI W, et al.The relationship between ITPArs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients[J].Medicine (Baltimore) , 2017, 96 (29) :e7554.

[7]OCHI H, MAEKAWA T, ABE H, et al.ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients[J].Gastroenterology, 2010, 139 (4) :1190-1197.

[8]WANG ML, PAN Y, JIANG J, et al.Association between ITPAgene variation and anemia during treatment with interferon combined with ribavirin[J].Chin J Gerontol, 2013, 33 (12) :2759-2761. (in Chinese) 王茉莉, 潘煜, 姜晶, 等.ITPA基因变异与干扰素联合利巴韦林治疗过程中发生贫血的相关性[J].中国老年学杂志, 2013, 33 (12) :2759-2761.

[9]HOLMES JA, ROBERTS SK, ALI RJ, et al.ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response[J].Hepatology, 2014, 59 (6) :2152-2160.

[10]THOMPSON AJ, FELLAY J, PATEL K, et al.Variants in the IT-PA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction[J].Gastroenterology, 2010, 139 (4) :1181-1189.

[11]DENG HH, XU M, LI XQ, et al.Correlation of inosine triphosphate pyrophosphatase single nucleotide polymorphism and ribavirin-related anemia in patients with chronic hepatitis C in Guangzhou[J/CD].Chin J Exp Clin Infect Dis:Electronic E-dition, 2017, 11 (2) :168-171. (in Chinese) 邓浩辉, 许敏, 李晓强, 等.广州地区丙型肝炎患者肌苷三磷酸酶基因多态性与利巴韦林所致贫血的相关性[J/CD].中华实验和临床感染病杂志:电子版, 2017, 11 (2) :168-171.

[12]VAN VLIERBERGH H, deLANGHE JR, de VOS M, et al.Factors influencing ribavirin-induced hemolysis[J].J Hepatol, 2001, 34 (6) :911-916.

[13]NOMURA H, TANIMOTO H, KAJIWARA E, et al.Factors contributing to ribavirin-induced anemia[J].J Gastroenterol Hepatol, 2004, 19 (11) :1312-1317.

[14]TAKAKI S, TSUBOTA A, HOSAKA T, et al.Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C[J].J Gastroenterol, 2004, 39 (7) :668-673.

Relative Articles

[1]	Li LIU, Lixian CHANG, Zhiyong CHEN, Junyi LI, Chunyun LIU. Efficacy and safety of sofosbuvir/velpatasvir alone or in combination with ribavirin in treatment of patients with genotype 3B HCV/HIV infection[J]. Journal of Clinical Hepatology, 2024, 40(2): 271-277. doi: 10.12449/JCH240209
[2]	Jinfeng XU, Lixia QIU, Haibin YU, Yirong LIU, Jing ZHANG, Yali LIU, Wei LIN. Association of inosine triphosphate pyrophosphatase gene polymorphisms with ribavirin combined with direct-acting antiviral agent in treatment of hepatitis C patients with hemolytic anemia[J]. Journal of Clinical Hepatology, 2021, 37(10): 2320-2323. doi: 10.3969/j.issn.1001-5256.2021.10.012
[3]	Ruan FangMing, Li BiMin. Risk factors for the formation of portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 182-185. doi: 10.3969/j.issn.1001-5256.2020.01.043
[4]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[5]	Bai Xue, Ma ZuoHong, Hao ZhiQiang, Fu XiBo, Jiao Ao, Shang Hai, Hua XiangDong. Research advances in the risk factors for microvascular invasion in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(11): 2578-2581. doi: 10.3969/j.issn.1001-5256.2019.11.042
[6]	Chang XiuJuan, Lu YinYing, Rong GuangHua, Liu Ze, Chen Yan, Xu GuiLin, Gao XuDong, Lou Min, Wang ChunPing, Yang YongPing, Ceng Zhen. Risk factors for vascular invasion of primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(5): 1038-1041. doi: 10.3969/j.issn.1001-5256.2018.05.022
[7]	Hu WeiLin. Risk factors for hypertriglyceridemia-induced acute pancreatitis[J]. Journal of Clinical Hepatology, 2017, 33(8): 1518-1521. doi: 10.3969/j.issn.1001-5256.2017.08.022
[8]	Wang FengJiao, Liu MingJiang, Wu RuiHong, Niu JunQi. A multivariate logistic regression analysis of short-term prognosis of patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2017, 33(4): 711-714. doi: 10.3969/j.issn.1001-5256.2017.04.022
[9]	Zhou RenHua, Li Peng, Zhang YanTing, Yang Hua, Yang ShaoQi. Clinical manifestations of portal vein thrombosis and related risk factors in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(2): 275-278. doi: 10.3969/j.issn.1001-5256.2016.02.015
[10]	Chen BiHua, Zhang Wei, Wu Pei, Huang Ying. Research advances in risk factors for primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(12): 2088-2092. doi: 10.3969/j.issn.1001-5256.2015.12.024
[11]	Sun JianMin, Hu QingJun. Relevance between relapse and course of treatment in genotype 1 chronic hepatitis C patients with slow virologic response[J]. Journal of Clinical Hepatology, 2015, 31(4): 560-563. doi: 10.3969/j.issn.1001-5256.2015.04.020
[12]	Sun JianMin. Efficacy of low-dose interferon α-1b combined with ribavirin and thymosin α1 versus standard treatment for chronic hepatitis C: a comparative study [J]. Journal of Clinical Hepatology, 2015, 31(1): 107-109. doi: 10.3969/j.issn.1001-5256.2015.01.023
[13]	Zhang YueRong, Zhou Ning, Li XiangLin, Wu LiYang, Wei ShiFang, Zhang YaoDi, Zhang YuePing. Causes and countermeasures for relapse after drug withdrawal in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2015, 31(9): 1434-1438. doi: 10.3969/j.issn.1001-5256.2015.09.017
[14]	Cai ShaoPing, Zhang WenJin, He WeiPing, Fan ZhenPing, Ji YingJie. Efficacy and safety of interferon plus ribavirin in elderly patients with chronic hepatitis C: report of 4 cases[J]. Journal of Clinical Hepatology, 2014, 30(1): 69-71. doi: 10.3969/j.issn.1001-5256.2014.01.019
[15]	Zhang SuMei, Xie YuMei, Zhang Ying, Guo YongHong, Wei Xin, Jiang Na, Zhou Yun, Jia ZhanSheng. Potential of G-CSF supplementation to counter the neutrophil effects of standard PEG-IFNα plus ribavirin combination therapy for treating HCV-related cirrhosis [J]. Journal of Clinical Hepatology, 2013, 29(5): 348-351.
[16]	Zhao XiaoLing, Zhang YongGang. Clinical efficacy of ribavirin combined with different doses of interferon α- 2b in patients with chronic hepatitis C genotypes 2 and 3[J]. Journal of Clinical Hepatology, 2013, 29(10): 780-783. doi: 10.3969/j.issn.1001-5256.2013.10.014
[17]	Zhu Yan, Mao Qing, Zhang ZhangJiang, Sun Wei, Hu YaJun, Tan ChaoXia, Wang XiaoHong. Retreatment with pegylated interferon alpha-2a/2b and ribavirin in previous relapsers with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(1): 86-88.
[18]	Jiang XueQiang, Zou XiaoJing, Tian DeYing. Virological response of chronic hepatitis C treated with peg-interferon α-2a and Ribavirin[J]. Journal of Clinical Hepatology, 2011, 27(4): 417-419.
[19]	Hao KunYan, He ZhangLun, Yu LeCheng, Sheng YunFeng, Wang MaoRong. Rhabdomyolysis during the antiviral therapy against chronic hepatitis C with the combination of interferon and ribavirin:a case report[J]. Journal of Clinical Hepatology, 2011, 27(6): 654-655.
[20]	Zheng YingYing, Fan XiaoHong, Wang LiFen, Tian Di, Huo Na, Lu HaiYing, Wu ChiHong, Xu XiaoYuan, Wei Lai. Efficacy and side effects of PEG-IFNα-2a plus ribavirin on elderly patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(8): 821-823.

Supplements(0)

Cited By

Cited by

Periodical cited type(7)

1.	欧阳宇，刘小波，吴晶. 索非布韦联合达卡他韦治疗代偿性丙型肝炎肝硬化的临床疗效. 临床合理用药杂志. 2022(27): 108-111 .
2.	张梅，杨永生，韩金鹏，周惠娟，刘霞. 聚乙二醇干扰素α-2a联合RBV抗病毒治疗慢性丙型肝炎患者疗效及对血清HCV RNA水平和不良反应的影响. 中国医学创新. 2021(12): 127-130 .
3.	徐金凤，仇丽霞，于海滨，刘义荣，张晶，柳雅立，林伟. 三磷酸次黄嘌呤核苷基因多态性对利巴韦林联合直接抗病毒药物治疗丙型肝炎致溶血性贫血的预测价值. 临床肝胆病杂志. 2021(10): 2320-2323 . 本站查看
4.	周静，陆宇红，王欣. 利巴韦林联合索磷布韦及达拉他韦治疗基因1b型低病毒载量慢性丙型肝炎疗效. 肝脏. 2021(10): 1154-1156+1169 .
5.	尚月华. 聚乙二醇干扰素、利巴韦林联合治疗慢性丙型肝炎的临床效果观察. 中国现代药物应用. 2020(03): 152-153 .
6.	师雁媛. 达拉他韦联合索磷布韦治疗1b型慢性丙型肝炎的效果观察. 中国实用医刊. 2020(09): 104-107 .
7.	李达，赵菊花，何启敏，王洁，杨羽. 三联药物方案对重型麻疹患者近期疗效与合并症的影响. 西部医学. 2019(11): 1753-1756 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1945) PDF downloads(299)

Influencing factors for hemolytic anemia in patients with chronic hepatitis C treated by ribavirin combined with pegylated interferon-α

DOI: 10.3969/j.issn.1001-5256.2019.02.015